# Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

> **NCT02312037** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- CD33 Positive Acute Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** Antibody Drug Conjugate Chemotherapeutic

## Key facts

- **NCT ID:** NCT02312037
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312037, "Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02312037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*